Nancy Stuart - 30 Jan 2023 Form 4 Insider Report for CONCERT PHARMACEUTICALS, INC.

Reporting relationship: Chief Operating Officer
Issuer ticker: N/A
Reported as of: 30 Jan 2023
Net transaction value: -$110,220
SEC form: 4
Accepted by SEC: 31 Jan 2023, 07:30:42 UTC
Prior SEC filing: 09 Jan 2023
Next SEC filing: 16 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey A. Munsie, attorney-in-fact

Key filing fact

Nancy Stuart filed Form 4 for CONCERT PHARMACEUTICALS, INC. on 31 Jan 2023.

Key facts

This page summarizes Nancy Stuart's Form 4 filing for CONCERT PHARMACEUTICALS, INC..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 31 Jan 2023, 07:30.

Change

Previous filing in this sequence was filed on 09 Jan 2023.
Current net transaction value: -$110,220.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CNCE transaction

Common Stock

Sale

Transaction value: $110,220
Shares: -13,200
Change %: -4.7%
Price: $8.35
Shares after: 268,644
Date: 30 Jan 2023
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This sale was effected pursuant to a Rule 10b5-1 trading plan entered into on June 28, 2022.

Footnote F2

These shares were sold to satisfy tax obligations associated with the vesting of restricted stock units.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.34 to $8.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.